文献速递肾移植

肾移植后抗CD19 CAR-T治疗继发T细胞介导排斥反应病例

Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report.
PubMed 文献 · Am J Kidney Dis · 2021-08-27

本文报告一名40岁肾移植受者,移植后5年发生伴11q异常的Burkitt样淋巴瘤,3线化疗失败后接受抗CD19 CAR-T细胞挽救治疗。CAR-T输注3个月后发生IIB级T细胞介导排斥反应,伴严重肾小管炎(T3)、轻度间质炎症(I1)及严重内膜动脉炎(V2)伴血液渗出;移植物浸润T细胞中部分表达抗CD19 CAR,移植物及血样本中亦通过微滴数字PCR检出CAR-T细胞。经糖皮质激素治疗后移植肾功能改善并保持稳定,但淋巴瘤进展,CAR-T输注10个月后患者因巨大肺部肿块死亡。

要点

  • 肾移植受者接受抗CD19 CAR-T后可发生T细胞介导排斥反应,需警惕。
  • 本例排斥反应为IIB级,伴严重肾小管炎与内膜动脉炎。
  • 糖皮质激素治疗后移植肾功能改善,但淋巴瘤进展最终致死。

核心结论

  • 肾移植后抗CD19 CAR-T细胞治疗可继发T细胞介导排斥反应,本例经糖皮质激素治疗后移植肾功能改善并稳定,但淋巴瘤仍进展并致患者死亡。

研究设计与样本

  • 个案报告:1例40岁肾移植受者,移植后5年发生伴11q异常的Burkitt样淋巴瘤,3线化疗失败后接受抗CD19 CAR-T细胞挽救治疗。

主要发现

  • CAR-T输注3个月后发生IIB级T细胞介导排斥反应,表现为严重肾小管炎(T3)、轻度间质炎症(I1)和严重内膜动脉炎(V2)伴血液渗出。
  • 移植物浸润T细胞中部分表达抗CD19 CAR,移植物及血样本中通过微滴数字PCR检出CAR-T细胞。
  • 经糖皮质激素治疗后移植肾功能改善并保持稳定;但淋巴瘤进展,出现巨大肺部肿块,CAR-T输注10个月后患者死亡。

临床怎么用

  • 肾移植受者接受抗CD19 CAR-T细胞治疗后应监测移植肾功能及排斥反应,本例提示糖皮质激素治疗可改善移植肾功能。

局限性

  • 为单例病例报告,结论外推受限;原文未报告CAR-T细胞剂量、排斥反应具体治疗方案及随访检测细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Post-transplant lymphoproliferative disorder is a growing complication of kidney transplantation and is associated with a poor prognosis. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is an important new treatment option modifying the outcome of refractory hematological cancers. Here, we report the case of a 40-year-old kidney transplant recipient who developed a Burkitt-like lymphoma with 11q aberration 5 years after transplantation. After 3 unsuccessful lines of chemotherapy, it was decided to treat the patient with anti-CD19 CAR T cells as a salvage therapy. Three months after CAR T-cell infusion, she experienced a grade IIB T cell-mediated rejection with severe tubulitis (T3), slight interstitial inflammation (I1), and severe intimal arteritis (V2) with blood suffusion. Among T cells infiltrating the graft, some of them expressed the anti-CD19 CAR. CAR T cells within the graft and in blood samples were also detected by droplet digital polymerase chain reaction. Function of the kidney transplant improved after corticosteroid treatment and remained stable. However, lymphoma progressed, with a massive pulmonary mass leading to the patient's death 10 months after CAR T-cell infusion.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. de Nattes T, Camus V, François A, et al. Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report. Am J Kidney Dis. 2021. PMID: 34461166. doi:10.1053/j.ajkd.2021.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。